Physician profile
Jonathon Baccus
NPI 1154700722
$1,220.82
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $104 · 2021: $700 · 2022: $183.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.57 | 2019-2022 | |
| Abbvie INC. | $130.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $112.99 | 2019-2022 | |
| Pfizer INC. | $109.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $74.54 | 2019-2022 | |
| Abbott Laboratories | $56.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.75 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $21.49 | 2021 | |
| Almatica Pharma LLC | $20.14 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.90 | 2021 | |
| Astellas Pharma US INC | $16.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.20 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13.87 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.63 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Baccus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.